全部所有文章
-
UBP Obtained the Building Use Permit for its Industry-scale Protein Drug Manufacturing Facility
UBP Obtained the Building Use Permit for its Industry-scale Protein Drug Manufacturing FacilityUBP Obtained the Building Use Permit for its Industry-scale Protein Drug Manufacturing Facilitymore -
National Institute of Health Study: UB-421’s HIV Suppression is Superior to 4 Other Broadly Neutralizing Antibodies
National Institute of Health Study: UB-421’s HIV Suppression is Superior to 4 Other Broadly Neutralizing AntibodiesNational Institute of Health Study: UB-421’s HIV Suppression is Superior to 4 Other Broadly Neutralizing Antibodiesmore -
UB-421抑制愛滋病毒效果優於國際知名抗愛滋病毒中和抗體，數據發表於新英格蘭醫學期刊
UB-421抑制愛滋病毒效果優於國際知名抗愛滋病毒中和抗體，數據發表於新英格蘭醫學期刊UB-421抑制愛滋病毒效果優於國際知名抗愛滋病毒中和抗體，數據發表於新英格蘭醫學期刊more -
United BioPharma Closes A Fundraising of NT$ 500 Million
United BioPharma Closes A Fundraising of NT$ 500 MillionUnited BioPharma Closes A Fundraising of NT$ 500 Millionmore -
工業合作案引進蛋白質藥物量產技術促進國內生技製藥產業升級 是一大突破
工業合作案引進蛋白質藥物量產技術促進國內生技製藥產業升級 是一大突破工業合作案引進蛋白質藥物量產技術促進國內生技製藥產業升級 是一大突破more -
United BioPharma to establish industrial protein drug manufacturing process via ICP program
United BioPharma to establish industrial protein drug manufacturing process via ICP programUnited BioPharma to establish industrial protein drug manufacturing process via ICP programmore -
Discover the BioManufacturing Solutions and Beyond
Discover the BioManufacturing Solutions and BeyondDiscover the BioManufacturing Solutions and Beyondmore -
United BioPharma Receives Technology Enterprise Qualification Planning for IPO soon
United BioPharma Receives Technology Enterprise Qualification Planning for IPO soonUnited BioPharma Receives Technology Enterprise Qualification Planning for IPO soonmore -
UBP Presents at Antibody Drug Development Conference Plans to submit Phase I Clinical Trial application in 2017 for UB-221, a third-generation anti-IgE monoclonal antibody drug
UBP Presents at Antibody Drug Development Conference Plans to submit Phase I Clinical Trial application in 2017 for UB-221, a third-generation anti-IgE monoclonal antibody drugUBP Presents at Antibody Drug Development Conference Plans to submit Phase I Clinical Trial application in 2017 for UB-221, a third-generation anti-IgE monoclonal antibody drugmore
